Search Results

Displaying: 25 / 100 / 200 results

Ordered by: Date (newest first) / Date (oldest first)

A risky business

28 August 2015 In the Pipeline

Graduate research is likely the most risky time of a chemist’s career, says Derek Lowe

A precision instrument?

30 July 2015 In the Pipeline

Chemists and biologists have different expectations when it comes to data, says Derek Lowe

Missing the target

23 June 2015 In the Pipeline

There are plenty of things that small molecule drugs can’t touch, says Derek Lowe, and it’s not for want of trying

Magic molecule modifiers

29 May 2015 In the Pipeline

Late stage functionalisation can seem supernaturally powerful, says Derek Lowe – if you’ve got the nerve to try it

Missing mathematics?

29 April 2015 In the Pipeline

While you may not need differential calculus every day, mathematics is the basis of scientific thinking, says Derek Lowe

Analogues by catalogue

24 March 2015 In the Pipeline

Buying in screening compounds directly feels like cutting out the synthetic chemist middleman, says Derek Lowe

Tantalising technology

20 February 2015 In the Pipeline

Computer-assisted drug design always looks like it’s just about to work, says Derek Lowe, but the reality is complicated

The smell of success

11 February 2015 In the Pipeline

Laboratory aromas conjure memories and emotions from elation to a sudden need to vomit, says Derek Lowe

Ignorance is no defence

14 January 2015 In the Pipeline

In a chemistry lab, what you don’t know really can hurt you, says Derek Lowe

Progress at the pace of the slowest

1 December 2014 In the Pipeline

Chemistry is rarely the rate-limiting process in getting a drug to market, says Derek Lowe

Chemical space is big. Really big.

28 October 2014 In the Pipeline

You think it’s a long way to the back of your screening libraries? That’s peanuts to chemical space, says Derek Lowe

Garbage in, garbage out

29 September 2014 In the Pipeline

The rise of low-quality and predatory open access journals and conferences worries Derek Lowe

Death of a reagent

22 August 2014 In the Pipeline

Fashion and progress combine to mean some reactions and reagents persist, while others fall by the wayside, says Derek Lowe

The crystal ball that can tell lies

29 July 2014 In the Pipeline

X-ray structures are not necessarily definitive, says Derek Lowe, especially when it comes to biomolecules

Too big to innovate?

25 June 2014 In the Pipeline

How strong is the correlation between company size and research productivity, asks Derek Lowe

Messy megamergers

29 May 2014 In the Pipeline

Big company buyouts are more about immediate gains and rarely consider the impact on research, says Derek Lowe

Engineering serendipity

25 April 2014 In the Pipeline

It takes more than random stumbling to find new reactions, says Derek Lowe

Known unknowns

27 March 2014 In the Pipeline

New molecules with unpredictable biological activity deserve sensible amounts of respect, says Derek Lowe

Tools of the trade

24 February 2014 In the Pipeline

Derek Lowe wonders what the most life-changing instrument for organic chemists is, and what might be missing from the toolbox

Beelzebub Pharma Ltd

31 January 2014 In the Pipeline

Derek Lowe thinks the Devil's R&D management schemes might be scarily familiar

Is there a drug for that?

7 January 2014 In the Pipeline

Derek Lowe ponders whether anything is truly ‘undruggable’ if we look in the right places

Rolling boulders uphill

27 November 2013 In the Pipeline

Is Derek Lowe troubled by his failure to develop a compound that has made it to the pharmacy shelf?

Natural born chemists

31 October 2013 In the Pipeline

Redesigning nature's catalysts is tantalising but tricky, says Derek Lowe

What's the use?

25 September 2013 In the Pipeline

Not every reaction can be run in a bucket, says Derek Lowe, but there are limits to what should be classed as ‘useful’

The never-ending story

2 September 2013 In the Pipeline

Keeping up with the literature is impossible, says Derek Lowe.